Cargando…

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View

SIMPLE SUMMARY: Hepatocellular carcinoma is the second most common cause of cancer-related deaths and accounts for over eighty percent of primary liver cancers worldwide. Regarding the Milan Criteria, only a small portion of HCC patients are eligible for liver transplantation due to advanced-stage d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelrahim, Maen, Esmail, Abdullah, Saharia, Ashish, Abudayyeh, Ala, Abdel-Wahab, Noha, Diab, Adi, Murakami, Naoka, Kaseb, Ahmed O., Chang, Jenny C., Gaber, Ahmed Osama, Ghobrial, Rafik Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997123/ https://www.ncbi.nlm.nih.gov/pubmed/35406533 http://dx.doi.org/10.3390/cancers14071760

Ejemplares similares

Transplant Oncology: An Emerging Discipline of Cancer Treatment
por: Abdelrahim, Maen, et al.
Publicado: (2023)

Transplant Oncology: An Evolving Field in Cancer Care
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology
por: Abboud, Karen, et al.
Publicado: (2023)

Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

Utility of Cell-Free DNA Detection in Transplant Oncology
por: Reddy, Tejaswini, et al.
Publicado: (2022)

Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
por: Parvathareddy, Vishnupriyadevi, et al.
Publicado: (2023)

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
por: Abdelrahim, Maen, et al.
Publicado: (2021)

Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center
por: Yi, Stephanie G., et al.
Publicado: (2020)

Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
por: Zhang, Yuqi, et al.
Publicado: (2022)

Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?
por: Abudayyeh, Ala, et al.
Publicado: (2015)

Checkpoint inhibitor-related renal vasculitis and use of rituximab
por: Mamlouk, Omar, et al.
Publicado: (2020)

RNAi and cancer: Implications and applications
por: Abdelrahim, Maen, et al.
Publicado: (2006)

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
por: Mamlouk, Omar, et al.
Publicado: (2019)

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
por: Badheeb, Mohamed, et al.
Publicado: (2022)

Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
por: Lin, Jamie S., et al.
Publicado: (2021)

Progress in Combined Liver–lung Transplantation at a Single Center
por: Connor, Ashton A., et al.
Publicado: (2023)

Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers
por: Connor, Ashton A., et al.
Publicado: (2022)

Macrophage Proinflammatory Responses to Microorganisms and Transplanted Organs
por: Kloc, Malgorzata, et al.
Publicado: (2020)

Chronic allograft rejection: A significant hurdle to transplant success
por: Kloc, Malgorzata, et al.
Publicado: (2014)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma
por: Hedrick, Erik, et al.
Publicado: (2015)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury
por: Abudayyeh, Ala, et al.
Publicado: (2022)

Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Not transplanting kidney donors with acute kidney injury: a missed opportunity?
por: Murakami, Naoka, et al.
Publicado: (2019)

B-cell response in solid organ transplantation
por: Yi, Stephanie G., et al.
Publicado: (2022)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation
por: Saberian, Chantal, et al.
Publicado: (2021)

Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine
por: Yi, Stephanie G., et al.
Publicado: (2021)

RhoA- and Actin-Dependent Functions of Macrophages from the Rodent Cardiac Transplantation Model Perspective -Timing Is the Essence
por: Kloc, Malgorzata, et al.
Publicado: (2021)

Intermediate-Term Outcomes of Dual Adult versus Single-Kidney Transplantation: Evolution of a Surgical Technique
por: Islam, Ana K., et al.
Publicado: (2016)

COVID-19 mortality may be reduced among fully vaccinated solid organ transplant recipients
por: Sandoval, Micaela, et al.
Publicado: (2022)

Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
por: Haque, Emaan, et al.
Publicado: (2022)

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab
por: Qureshi, Sehrish, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_onotp575hlasnj16loki9e8ihr